Chennai, Sep 1 (IANS): India's Sun Pharmaceutical Industries Ltd. on Tuesday said it has started the process of integrating its opiates business in Australia.

The company had completed the acquisition of the opiates business from GlaxoSmithKline (GSK).

Sun Pharma announced the acquisition in March 2015.

According to Sun Pharmaceuticals, the acquisition fortifies the company's global position with two opiates manufacturing facilities in Port Fairy and Latrobe (both in Australia) complementing its current active pharmaceutical ingredients (API) manufacturing footprint globally.

Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs.

It also brings a specialised team to drive business growth.

The acquisition enables Sun Pharma to expand its narcotics raw material (NRM) market share and enhance opiate alkaloids portfolio.